Gjalt W. Huisman

TL;DR: Applications of protein-engineered biocatalysts ranging from commodity chemicals to advanced pharmaceutical intermediates that use enzyme catalysis as a key step are discussed.

TL;DR: An overview of the different PHA biosynthetic systems and their genetic background is provided, followed by a detailed summation of how this natural diversity is being used to develop commercially attractive, recombinant processes for the large-scale production of PHAs.

TL;DR: An efficient biocatalytic process to replace a recently implemented rhodium-catalyzed asymmetric enamine hydrogenation for the large-scale manufacture of the antidiabetic compound sitagliptin is reported, underscoring the maturation of bioc atalysis to enable efficient, economical, and environmentally benign processes for the manufacture of pharmaceuticals.

TL;DR: A directed evolution approach is described that augments recombination-based directed evolution by incorporating a strategy for statistical analysis of protein sequence activity relationships (ProSAR), which facilitates mutation-oriented enzyme optimization by permitting the capture of additional information contained in the sequence-activity data.

TL;DR: In vitro enzyme evolution using gene shuffling technologies was employed to optimise their performance according to predefined criteria and process parameters, which afforded a 2500-fold improvement in the volumetric productivity per biocatalyst loading.